It is crucial to distinguish between circulating cholesterol levels and the intrinsic reprogramming of cholesterol metabolism in tumor cells, which may involve upregulation of pathways or adaptive mechanisms, such as increased LDL receptor (LDLR) expression to compensate for impaired synthesis [63, 64]. The gene discussed is LDLR; the disease is neoplasm.